Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells

Young Lee1,2, Eric D. Berglund1,2, Xinxin Yu3, May-Yun Wang3, Matthew R. Evans3, Philipp E. Scherer4, William L. Holland5, Maureen J. Charron6,7, Michael G. Roth6,2,1 and Roger H. Unger8

1Touchstone Diabetes Center, Department of Internal Medicine, 2Advanced Imaging Center and Department of Pharmacology, and 3Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390; and Departments of 4Biochemistry, 5Obstetrics and Gynecology and Woman’s Health, Albert Einstein College of Medicine, Bronx, NY 10461

Edited by Donald F. Steiner, The University of Chicago, Chicago, IL, and approved July 29, 2014 (received for review May 23, 2014)

To determine the role of glucagon action in diet-induced and genetic type 2 diabetes (T2D), we studied high-fat-diet-induced obese (DIO) and leptin receptor-defective (LeprΔ/Δ) rodents with and without glucagon receptors (GcgRs). DIO and LeprΔ/Δ, GcgR+/− mice both developed hyperinsulinemia, increased liver sterol response element binding protein 1c, and obesity. DIO GcgR−/− mice developed mild T2D, whereas LeprΔ/Δ, GcgR+/− mice developed severe T2D. High-fat-fed (HFF) glucagon receptor-null mice did not develop hyperinsulinemia, increased liver sterol response element binding protein 1c mRNA, or obesity. Insulin treatment of HFF GcgR−/− to simulate HFF-induced hyperinsulinemia caused obesity and mild T2D. LeprΔ/Δ, GcgR+/− did not develop hyperinsulinemia or hyperglycemia. Adenoviral delivery of GcgR to GcgR−/− mice caused the severe hyperinsulinemia and hyperglycemia of LeprΔ/Δ mice to appear. Spontaneous disappearance of the GcgR transgene abolished the hyperinsulinemia and hyperglycemia. In conclusion, T2D hyperglycemia requires unsuppressible hyperglucagonemia from insulin-resistant α cells and is prevented by glucagon suppression or blockade.

Conarello et al. (20), which had suggested that, in the absence of GcgR and hyperinsulinemia, obesity could not be induced by high-fat feeding (HFF). We placed wild-type (GcgR+/+) and GcgR−/− mice on a 60% fat diet with 10% sucrose in the drinking water. As shown in Fig. S1 A–D, after 10 wk on this diet, body fat of GcgR−/− mice did not increase significantly, and they did not become hyperinsulinemic or hyperglycemic, in contrast to the GcgR+/+ mice.

Glcucagon Action on Beta Cells in Diet-Induced Hyperinsulinemia. The lack of diet-induced hyperinsulinemia in GcgR−/− mice could be either the consequence of loss of a direct action of glucagon on beta cells (21), the prevention of hyperglycemia, or failure of the GcgR+/− liver to generate a betatrophin-like hepatokine (22). To obtain evidence for a direct glucagon action on beta cells, we cultured rat insulinoma Ins-1 cells in 11 mM glucose with or without 0.4 μg/mL of glucagon (Sigma) for 24 h. In the presence of glucagon, proinsulin mRNA increased threefold and insulin release into the medium by 30% (P < 0.05; Fig. 1A). We conclude that glucagon can directly up-regulate insulin expression, but stimulation by hyperglycemia or by a hepatokine in vivo was not excluded.

Glcucagon Action on Metabolic Parameters. To understand more fully the fate of the ingested calories in the resistance of GcgR−/− mice to obesity, three mice from each group were studied in a metabolic cage. GcgR−/− mice on a 60% high-fat diet consumed an average of 12 kcal per day, ∼1/3 higher than on a chow diet (P < 0.05).

Significance

Diet-induced type 2 diabetes (T2D) is becoming a worldwide epidemic. Patients with T2D fail to respond to insulin normally and have elevated blood glucose and insulin. In autoimmune diabetes, blood glucose is elevated due to uncontrolled glucagon, a hormone normally suppressed and opposed by insulin. To study the role of glucagon in T2D, rodent models of the disease were created lacking glucagon action. These animals failed to develop hyperglycemia unless glucagon action was restored or the animals were given the high concentrations of insulin typical of animals with T2D. This indicates that the unopposed glucagon action in T2D is necessary to support elevated blood glucose of diabetes. Suppressing glucagon or its action may benefit patients with T2D.


Conflict of interest statement: R.H.U. and M.G.R. are founding scientists of SynAlpha Therapeutics, LLC.

This article is a PNAS Direct Submission.

1Y.L. and E.D.B. contributed equally to this work.
2To whom correspondence should be addressed. Email: michael.roth@utsouthwestern.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1409638111/-/DCSupplemental.
Body fat rose \( \sim 500\% \) from 3.5 g to 15 g at 120 d \((P < 0.001)\).

\( \text{GcgR}^{-/-} \) mice on the high-fat diet ate 9.4 kcal per day, 25\% less food than \( \text{GcgR}^{+/+} \) mice \((P < 0.05)\), but their caloric intake rose only 1 kcal/d above that of \( \text{GcgR}^{-/-} \) mice on the chow diet (Table 1).

They gained only 2.5 g of body fat, only 20\% of the weight gain in the \( \text{GcgR}^{+/+} \) controls \((P < 0.001)\). HFF decreased physical activity of \( \text{GcgR}^{+/+} \) mice by \( \sim 14\% \), whereas no change in physical activity was observed in \( \text{GcgR}^{-/-} \) mice, which were half as active as \( \text{GcgR}^{+/+} \) mice on either diet. There were no changes in core temperature. \( \text{VO}_2 \) and \( \text{VCO}_2 \) were significantly reduced in \( \text{GcgR}^{-/-} \) mice.

![Fig. 1.](image)

(A) The effect of glucagon on preproinsulin mRNA in INS-1 cells cultured for 24 h in 0 or 0.4 \( \mu \text{g/mL} \) of glucagon (Left). (Right) Mean insulin concentration in the medium after 24 h incubation of INS-1 cells in the absence or presence of 0.4 \( \mu \text{g/mL} \) of glucagon. \( n = 3 \), and mean values \( \pm \text{SEM} \) are shown.

(B) Comparison of SREBP-1c expression in the liver of \( \text{GcgR}^{+/+} \) and \( \text{GcgR}^{-/-} \) mice on a chow diet (striped bar) and a diet of 60\% fat with sucrose supplementation in the absence (black bar) and in the presence (white bar) of treatment with exogenous insulin. The gray bar represents values from \( \text{GcgR}^{-/-} \) mice restricted to 75\% of the caloric intake of HFF \( \text{GcgR}^{+/+} \) mice. \( n = 6 \), and mean values \( \pm \text{SEM} \) are shown.

(C) The appearance of \( \text{GcgR}^{+/+} \) and \( \text{GcgR}^{-/-} \) mice fed a high-fat diet with sucrose supplementation (Left). (Right) A mouse treated with exogenous insulin. The mean plasma insulin concentration \( \pm \text{SEM} \) for six mice in each group appear under the representative photograph.

### Table 1. Body weight, food intake, total body fat, blood glucose, and plasma insulin

<table>
<thead>
<tr>
<th>Genotype, diet</th>
<th>Body weight, g</th>
<th>Food intake, kcal/d</th>
<th>Total body fat, g</th>
<th>Blood glucose, mg/100 mL</th>
<th>Plasma insulin, ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{GcgR}^{+/+} ) chow</td>
<td>29.3 ± 1.40</td>
<td>9.1 ± 1.0</td>
<td>3.56 ± 0.29</td>
<td>156 ± 4.5</td>
<td>1.6 ± 0.34</td>
</tr>
<tr>
<td>( \text{GcgR}^{+/+} ) HF</td>
<td>40.0 ± 1.46</td>
<td>12.0 ± 1.0</td>
<td>15.00 ± 1.16</td>
<td>201 ± 14.2</td>
<td>3.1 ± 0.30</td>
</tr>
<tr>
<td>( \text{GcgR}^{+/+} ) HF, 75%</td>
<td>35.0 ± 1.20</td>
<td>9.0 ± 0.1</td>
<td>13.10 ± 0.46</td>
<td>173 ± 11.3</td>
<td>3.4 ± 0.72</td>
</tr>
<tr>
<td>( \text{GcgR}^{+/+} ) chow</td>
<td>26.1 ± 1.16</td>
<td>8.4 ± 0.2</td>
<td>2.13 ± 0.25</td>
<td>116 ± 6.3</td>
<td>0.77 ± 0.1</td>
</tr>
<tr>
<td>( \text{GcgR}^{-/-} ) HF</td>
<td>29.6 ± 1.49</td>
<td>9.4 ± 0.5</td>
<td>4.50 ± 0.37</td>
<td>123 ± 9.4</td>
<td>2.1 ± 0.52</td>
</tr>
<tr>
<td>( \text{GcgR}^{-/-} ) HF + insulin</td>
<td>44.4 ± 0.33</td>
<td>10.3 ± 0.7</td>
<td>18.00 ± 0.13</td>
<td>150 ± 7.3</td>
<td>7.4 ± 1.80</td>
</tr>
</tbody>
</table>

\( n = 6 \) for each diet/treatment. Comparisons were evaluated by \( t \) test, and statistics are given in Results. HF, high fat.
Role of Hyperinsulinemia in Diet-Induced Lipogenesis and Its Complications. Given the well-established relationship between insulin and lipogenesis (23–25), failure of GcgR−/− mice to mount a hyperinsulinemic response to a high-fat diet is muted in SREBP-1c in response to a high-fat diet is muted in GcgR−/− mice on a low-fat diet and a high-fat diet (Fig. 1B). On a high-fat diet, SREBP1c expression in GcgR−/− and GcgR+/+ mice was the same. However, on the high-fat diet, SREBP1c mRNA expression was approximately eightfold in livers of GcgR−/− mice (P < 0.001) but only a twofold difference was observed in GcgR+/+ mice (P < 0.05). Thus, the up-regulation of the lipogenic transcription factor SREBP1c in response to a high-fat diet is muted in GcgR−/− mice.

In GcgR−/− mice, a 25% reduction of HFF lowered the high-fat-induced increase in SREBP1c mRNA by half, to fourfold above that in GcgR+/+ mice on a low-fat diet, which was still a significant difference (P < 0.05; Fig. 1B).

In view of the role of insulin in up-regulating SREBP1c (26) and the observation that Ins1+/−, Ins2−/− mice do not become obese upon HFF (27), one would expect simulation of diet-induced hyperinsulinemia with exogenous insulin to fatten HFF GcgR−/− mice to the level of the HFF wild-type mice. Therefore, we injected s.c. insulin pellets into GcgR−/− mice as they began the high-fat diet. After 10 wk of HFF, plasma insulin in peripheral venous blood averaged 7.4 ng/mL in insulin-treated GcgR−/− mice, compared with 3.1 ng of endogenous insulin per mL in fat-fed GcgR+/+ mice (P < 0.05; Table 1). However, because steady-state insulin levels of endogenous insulin in the portal vein average 2–3 times the peripheral arterial levels (28), it can be assumed that the levels of the GcgR−/− mice implanted with insulin pellets and those of the GcgR+/+ mice were exposed to relatively similar levels of hyperinsulinemia. As shown in Fig. 1C and Table 1, the insulin-treated HFF GcgR−/− mice became just as obese as the GcgR+/+ mice, evidence that hyperinsulinemia is an obligatory factor in the diet-induced obesity independent of its effects of suppressing glucagon. Liver SREBP1c mRNA, which is induced by insulin action (26), rose twofold in the insulin-treated GcgR+/+ mice (P < 0.05; Fig. 1B). Even though the insulin levels in the insulin-treated GcgR−/− mice were 3 times higher than in the untreated GcgR+/+ mice (7.4 ng/mL vs. 2.1 ng/mL, P < 0.05), their plasma glucose levels were significantly higher (150 ± 7.3 mg/dL vs. 123 ± 9.4 mg/dL, P < 0.05; Table 1). If taken literally, this would imply that the hyperinsulinemia induced IR and mild diabetes.

Role of Glucagon Action in T2D. Because the hyperglycemia in HFF GcgR−/− mice and in insulin-treated GcgR−/− mice was so marginal, we turned to more severe models of T2D caused by congenital deficiency of leptin signaling [both the spontaneously occurring db/db mice, engineered leptin receptor knockout leptinob/ob (29), and spontaneously occurring Zucker Diabetic fatty (ZDFob/ob) rats]. These leptin receptor-defective (LepR−/−) rodents become hyperinsulinemic at 10–14 d of age and identifiably obese at 21–28 d. In these genetic backgrounds, hyperglycemia typically begins between 5 and 10 wk of age. Initial hyperplasia of beta cells begins earlier and in ZDFob/ob rats persists for ~12 wk, after which depletion of beta cells begins, reaching a 75% loss by 4 mo. Hyperglycemia is difficult to control with insulin injections because of the marked insulin resistance. Hyperlipidemia, ectopic lipid accumulation, and evidence of lipotoxicity are apparent (30).

To determine if glucagon action plays a role in the pathogenesis of this form of T2D, we bred LepRloxTB (LepR−/−) mice with GcgR−/− mice to produce mice lacking normal versions of both leptin and glucagon receptors (LepR−/−,GcgR−/−). The LepR−/−,GcgR−/− mice were obese, weighing 45 ± 1.6 g on average, but less so than LepR−/−,GcgR+/+ mice (59 ± 4.3 g on average) (P < 0.05; Table 1). In normal mice with normal insulin levels, plasma glucose concentrations were well below the diabetic level of 200 mg/dL (P < 0.05; Fig. 2A). By contrast, LepR−/−,GcgR+/+ mice were diabetic, with a mean glucose concentration of 455 mg/dL, despite extreme hyperinsulinemia. However, in LepR−/−,GcgR−/− mice, glucose and insulin levels remained within the normal range (Fig. 2B), suggesting that in severe T2D caused by leptin receptor impairment, glucagon signaling is required for hyperglycemia. Thus, lack of glucagon signaling in LepR−/− mice prevented both severe hyperglycemia and the hyperinsulinemia.

To determine if the prevention of T2D in GcgR−/− mice was the result of congenital absence of GcgR, rather than a direct and immediate consequence of acute loss of glucagon signaling, we delivered GcgR by adenovirus to the liver of LepR−/−,GcgR−/− mice. The glucagon receptor mRNA appeared in the liver within 24 h and was expressed for about 7 d, after which it spontaneously disappeared. Within 24 h of the injection of adenovirus containing the GcgR cDNA into the LepR−/−,GcgR−/− mice, glucose rose fivefold to ~500 mg/dL and insulin levels rose more than 10-fold to ~50 ng/mL (Fig. 2B). Presumably, the insulin rise was a response to the severe hyperglycemia caused by the sudden abundance of transgenic GcgR in the liver. The hyperglycemia, which did not occur in LepR−/−,GcgR−/− mice with congenital lack of glucagon action, promptly appeared upon delivery of the GcgR transgene to their liver and persisted until spontaneous disappearance of the GcgR transgene (Fig. 2B). This signifies that the hyperglycemia of T2D, like that of T1D, cannot occur in the absence of glucose overproduction maintained by glucagon signaling in the liver. The rapid normalization of hyperglycemia after acute disappearance of GcgR mRNA suggests that acute suppression of glucagon action would be effective therapeutically.

LepR−/− mice had hyperglycemia despite insulin levels averaging 20 times the levels of wild-type mice (Fig. 2A). LepR−/−,GcgR−/− mice, by contrast, had normoglycemia and normal insulin levels, suggesting that lack of GcgR prevented both hyperglycemia and IR. When adenovirus-expressing GcgR was delivered to the liver of LepR−/−,GcgR−/− mice, hyperglycemia and hyperinsulinemia both disappeared within 24 h (Fig. 2B). We had previously reported the spontaneous disappearance of the GcgR transgene in mice within 8 d (16). In these LepR−/− mice, hyperglycemia above 200 mg/dL and hyperinsulinemia above 10 ng/mL persisted for 18 d (Fig. 2B).

Table 2. Metabolic cage measurements and rectal temperature for GcgR mice

<table>
<thead>
<tr>
<th>Genotype, diet</th>
<th>VO2, ml/h/kg</th>
<th>VCO2, ml/h/kg</th>
<th>Heat, kcal/h/kg</th>
<th>Central movement counts</th>
<th>Peripheral movement counts</th>
<th>Rectal temperature, °C</th>
</tr>
</thead>
<tbody>
<tr>
<td>GcgR+/+ chow</td>
<td>4,759 ± 257*</td>
<td>4,120 ± 261*</td>
<td>23.3 ± 1.3</td>
<td>5,179 ± 452</td>
<td>3,831 ± 287</td>
<td>38.2 ± 0.29</td>
</tr>
<tr>
<td>GcgR+/+ HF</td>
<td>4,958 ± 160</td>
<td>4,315 ± 131</td>
<td>24.3 ± 0.3</td>
<td>3,477 ± 337</td>
<td>3,505 ± 548</td>
<td>37.3 ± 0.13</td>
</tr>
<tr>
<td>GcgR−/− chow</td>
<td>3,489 ± 346*</td>
<td>2,699 ± 330*</td>
<td>16.7 ± 1.7</td>
<td>2,212 ± 335</td>
<td>2,053 ± 364</td>
<td>38.1 ± 0.15</td>
</tr>
<tr>
<td>GcgR−/− HF</td>
<td>4,021 ± 717</td>
<td>3,506 ± 835</td>
<td>19.5 ± 3.7</td>
<td>1,717 ± 128</td>
<td>2,410 ± 390</td>
<td>37.2 ± 0.34</td>
</tr>
</tbody>
</table>

*P < 0.05, comparing +/− to −/− on the same diet for VO2 and VCO2. HF, high fat.
These results suggest that GcgR is required for the hyperglycemia of T2D. However, they do not reveal the nature of the glucose-insulin relationship—that is, whether the high insulin is caused by the hyperglycemia or if the hyperglycemia reflects IR. The fact that liver triacylglycerol (TG) levels, which averaged 400 ± 11.0 mg/g of liver weight in LepR−/− mice (n = 4), remained at 125 ± 12.4 mg/g in LepR−/−,GcgR+/− mice (n = 4), more than 12 times the level of 10 ± 0.84 mg/g in normal mice (n = 6), points to persistence of lipid-induced IR as a possible explanation for the hyperglycemia occurring despite marked hyperinsulinemia.

Role of Ceramide in Alpha Cell Insulin Resistance. The accumulation of ceramide and other lipids has long been implicated in the pathogenesis of IR (31, 32). To determine if ceramide can mediate the resistance to insulin-mediated suppression of the hyperglucagonemia of T2D, we measured preproglucagon mRNA in cultured InR1-G9 alpha cells exposed to 200 μM of insulin with and without 50 μM ceramide. Without ceramide, insulin reduced preproglucagon mRNA by 46% (P < 0.05; Fig. 3A); with ceramide in the medium, insulin failed to lower it.

We had demonstrated previously (33) that ceramide suppression of gluca


then-thesis from palmitate is increased in islets isolated from rodent models of severe insulin resistance and T2D, such as db/db mice and ZDF/fa/fa rats. Their islets exhibited enhanced expression of serine palmitoyl transferase, the rate-limiting enzyme in ceramide synthesis (4). In this earlier work, ceramide was implicated in the dysfunction and lipo-apoptosis of beta cells in T2D. The present results suggest that ceramide excess, previously implicated in the insulin resistance in other targets (31, 32), may also cause resistance to insulin-mediated suppression of hyperglucagonemia.

The combination of ceramide-induced beta cell impairment and ceramide-induced insulin resistance of alpha cells would explain the insulin-unresponsive hyperglucagonemia in T2D patients (19). The low insulin-to-glucagon ratio would maintain hepatic overproduction of glucose during meals. The scheme offered in Fig. 3B links lipid-induced changes in islet cells to the hyperglycemia of T2D through lipotoxicity of both alpha and beta cells (4).

Therapeutic Implications of Glucagon Suppression in T2D. The results presented here could have important therapeutic implications. If as depicted in Fig. 3B glucagon enables the diet-induced hyperinsulinemia required to generate lipogenesis, obesity, and T2D, suppression of glucagon or its action should prevent T2D. To test this, we used a known glucagon suppressor, gamma-amino butyric acid (GABA), to treat ZDF/fa/fa rats, in which the phenotype of obesity, ectopic lipid deposition, IR, hyperglucagonemia, and T2D is caused by a defective LePR. Hyperglucagonemia was reduced to normal in the GABA-treated rats but not in the controls (Fig. 3C). These results appear to validate the pathogenic relationships depicted and imply that glucagon suppression or blockade would provide a potential defense against the pandemic of T2D.

Discussion

This study identifies a pathogenic pathway to the diet-induced diseases now plaguing Western countries. It identifies two essential pathogenic roles for glucagon in diet-induced T2D. One is the essential role of glucagon in all forms of hyperglycemia, that of maintaining a rate of hepatic glucose production exceeding the rate of glucose clearance (26, 28, 34, 35). The second, previously unsuspected role for glucagon is that of an enabler of the diet-induced hyperinsulinemia. Conarello et al. (21) reported that diet-induced hyperinsulinemia cannot occur in GcgR−/− mice, a finding that we have now confirmed. Without glucagon action, diet-enhanced lipogenesis and obesity cannot occur.

Although glucagon stimulates insulin in vivo (36), it is not clear if the effect is direct on beta cells or if it is mediated by a hepatokine such as betatrophin (22) or by the accompanying hyperglycemia. We demonstrate that Ins-1 cells exhibit increased insulin secretion and preproinsulin expression when treated with glucagon. This suggests direct paracrine glucagon signaling to beta

Table 3. Body weight, food intake, blood glucose, and insulin in LepR+/−,GcgR+/− mice

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Body weight, g</th>
<th>Food intake, kcal/d</th>
<th>Blood glucose, mg/100mL</th>
<th>Plasma insulin, ng/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>LepR+/−,GcgR+/−</td>
<td>59.0 ± 4.3*</td>
<td>22.4 ± 1.1**</td>
<td>455 ± 19.2**</td>
<td>38.1 ± 1.3**</td>
</tr>
<tr>
<td>LepR+/−,GcgR+/-</td>
<td>45.0 ± 1.6*</td>
<td>15.5 ± 1.1**</td>
<td>70 ± 5.0**</td>
<td>7.2 ± 1.5**</td>
</tr>
<tr>
<td>LepR+/−,GcgR−/−</td>
<td>48.0 ± 0.8</td>
<td>24.0 ± 1.7</td>
<td>391 ± 33.0**</td>
<td>31.0 ± 3.0</td>
</tr>
</tbody>
</table>

n = 6 for each diet/treatment. Body weight, food intake, blood glucose, and plasma insulin are significantly different (P < 0.05) comparing LepR+/−,GcgR+/− and LepR+/−,GcgR−/− mice. All four parameters are not significantly different comparing LepR+/−,GcgR+/− mice to LepR+/−,GcgR−/− treated with Adv-GgcR. Within a column, symbols indicate pairwise comparisons with P < 0.05.

Fig. 2. (A) Comparison of plasma glucose and insulin levels in GgcR+/+ (n = 6), GgcR+/- (n = 6), LepR+/−, GgcR+/− (n = 4), and LepR+/−, GgcR−/− mice (n = 4) treated with adenosine containing the GgcR cDNA. Blood glucose and insulin levels are significantly lower in LepR+/−, GgcR−/− mice compared with LepR+/−, GgcR+/− mice, P < 0.05. Treatment of LepR+/−, GgcR+/− mice with Adv-GgcR significantly raised blood glucose and insulin compared with LepR+/−, GgcR−/− mice not treated with Adv; P < 0.05. Treatment with Ad-g-beta Gal had no effect (Table S2). (B) The time course of mean blood glucose and plasma insulin levels of the LepR+/−, GgcR−/− mice following the injection of adenosine containing the GgcR cDNA. Errors are SEM.
There are potentially useful clinical lessons to be learned from these studies. First, suppressing glucagon secretion or blocking its action can prevent diet-induced hyperinsulinemia that mediates lipogenesis and obesity. It does so without causing diabetes, which in fact it prevents. Second, the evidence that diet-induced hyperinsulinemia is a pathogenic component in the chain that ends with obesity and T2D should deter the use of intensive insulin therapy to control the hyperglycemia of obese, hyperinsulinemic T2D patients (37, 38).

Materials and Methods

Animals and HFF. Twelve male C57BL6 wild-type GcgR+/− and GcgR−/− mice were housed in individual cages with constant temperature and 12 h of light alternating with 12 h darkness. Half the mice were fed a Teklad 6% (wt/wt) mouse/rat chow diet, and half of the mice were fed a 60% (wt/wt) high-fat diet (Research Diets Inc.) with 10% (wt/wt) sucrose water for 10 wk. Food intake, body weight, blood glucose, and total body fat were measured weekly. Total body fat was measured with a mq10 NMR analyzer (Bruker Biospin), all tissues were freeze-clamped, excised, frozen in liquid nitrogen immediately, and stored at −80 °C until use. Guidelines from the Institutional Animal Care and Use Committee of University of Texas Southwestern were followed.

LepR+/−, GcgR−/− Mice. Mice lacking both the glucagon and leptin receptor were generated by crossing GcgR−/− mice with recently described mice in which a loxP flanked stop sequence was inserted to disrupt expression of the leptin receptor (leprlox/TB) (39). Study animals were generated by breeding animals heterozygous for both GcgR and leprlox/TB.

Insulin Treatment. Six- to 12-wk-old GcgR−/− mice received insulin pellet (Linshin Canada Inc.) implants and were followed for 10 wk on the high-fat diet. Body weight and blood insulin were measured before and after the 10 wk.

Adenovirus GcgR Administration. Adv-GcgR was purchased from Vector Biolabs. Adv-GcgR or B-galactosidase was administered i.v. at a dose of 1 × 10^9 pfu/10 g.

Metabolic Cage Studies. GcgR+/− and GcgR−/− mice, which were fed either control chow or a 60% high-fat diet (three mice in each group), were housed in metabolic cages. VO2, VCO2, peripheral central movement, and food intake were measured.

ZDFfa/fa Rats Fed GABA. Twelve- to 6-wk-old male ZDFfa/fa rats were divided into two groups. The experimental group was placed on 10% GABA (Sigma) with a powder chow diet, and the other group was pair-fed with the same chow diet without GABA for 6 wk. Blood glucose was measured with a glucose meter around 10:00 AM every week with a glucose meter (Bayer HealthCare LLC).

Plasma Measurements. Blood glucose was measured in conscious animals from a hand-held glucose meter (Bayer HealthCare LLC) on tail vein blood around 10:00 AM weekly. Plasma insulin levels were measured using a rat/mouse insulin ELISA kit (Crystal Chem).

TG Content of Tissues. Total lipids from livers were extracted, and TG content was assayed as previously described (40). Four to six livers from each treatment condition were measured.

Quantitative Real-Time PCR. Total RNA was extracted from livers from mice and Ins-1 cells using Qiagen RNeasy kit, according to the manufacturer's protocol. The expression of mRNA was calculated by using the standard curve method, and 36B4 RNA level was used as the invariant control. Primer sequences of genes used for quantification of mRNA by quantitative PCRs are listed in Table S1.

Culture of Hamster Pancreatic InR1-G9 Cells. Mycoplasma-free InR1-G9 cells were cultured in RPMI medium 1640 with 10% FBS (GIBCO) and 1 mM sodium pyruvate (Invitrogen) and contained 1% of penicillin–streptomycin solution (Invitrogen). InR1-G9 cells gave the appropriate glucose-regulated glucagon secretion in the absence of insulin. To characterize the effect of ceramide directly on the alpha cell, 400,000 cells were plated per well in a 12-well tissue culture plate. The next day cells were treated with ceramide at the indicated concentrations. After 30 min, 0.2 mU cells, although a role for a glucagon-stimulated hepatokine such as betatrophin (22) was not excluded. These findings suggest novel strategies to combat the obesity/T2D epidemic. Using glucagon suppressors or blockers of GcgR, it should be possible to block the diet-induced hyperinsulinemia that is the sine qua non of obesity and the accompanying metabolic syndrome, in addition to simply preventing hyperglycemia by suppressing glucagon secretion.

Interference with diet-induced insulin secretion would be expected to cause diabetes. Remarkably, the lack of diet-induced obesity (DIO)-associated hyperinsulinemia in GcgR−/− mice did not cause hyperglycemia, probably because without glucagon action, glucose production by the GcgR−/− liver cannot exceed glucose clearance (35).

Lee et al.
insulin was added to the well for an additional 20 min before being harvested. Total RNA was extracted from the Qiagen RNeasy kit, and GAPDH was used as an internal control to normalize the variability in expression levels.

**Culture of Ins-1 Cells.** Ins-1 cells were cultured in RPMI medium 1640 with 10% FBS (Gibco), 1 mM sodium pyruvate, 1 mM Hepes, 1 mM Glutamax, and 1% of penicillin–streptomycin solution (Invitrogen). One million cells were plated in a six-well plate and treated with/without glucagon (0.4 μg/mL of medium) for 24 h. Total RNA was extracted from Ins-1 cells using Qiagen RNeasy kit, and 36B4 was used as an internal control to normalize the variability in expression levels.